Tagged with Access

Morocco Sanaa Sayagh of Roche Morocco shares her commitment to bringing the latest immunotherapies to Moroccan patients through partnerships with health authorities and the Lalla Salma Foundation on creative access programs. Sayagh also touches on how Roche is attempting to make personalised healthcare a reality in Morocco.   Despite the lack…

Mexico Earlier in 2020, PharmaBoardroom sat down with several key stakeholders in the Mexican healthcare and life sciences industry, from the leaders of multinational affiliates, start-up entrepreneurs, association heads, and key opinion leaders. Here, we round up three of their most talked about topics.   Government  One of the most talked-about…

Belgium Christos Andriopoulos, managing director of Merck, speaks about his experience transitioning from global operations to leading a country subsidiary. Andriopoulos goes on to explain the company’s unique positioning as an innovative specialty pharma player balancing a core business with an increasing focus on specialty areas. He also offers insights on…

Belgium Fréderic Covemaeker, general manager of Nordic Pharma Belgium, introduces the Belgian affiliate which he established himself in 2008 and elaborates on the next stage of development for operations as Nordic prepares to deliver new solutions to patients in areas with unmet medical needs. Covemaeker also speaks to the challenges faced…

Romania Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders, gastroenterology and endocrinology. She reveals that a successful market launch entails having a patient-centric approach, supporting patients not only with…

Pricing Pushback from drug companies on Canada’s newest drug pricing regulations has led the country’s regulatory body to reconsider their implementation. Companies cite the push for cost-effectiveness as a reason for withdrawing drug approval applications, cutting jobs, or delaying launches, claiming the new pricing regulations will substantially reduce revenues.    The…

Morocco Guillaume Recorbet, general manager of Servier in Morocco, explains Servier’s special status in the Moroccan pharma industry as a multinational company with a historic and extensive manufacturing footprint in the country, shares his three priorities to return the affiliate to the right track after a tough period following price cuts,…

Romania Attila Fejer general manager of Eli Lilly in Romania gives his insights on the “deadly cocktail” of challenging policies that govern the pharmaceutical industry in the country. He shares the new therapeutic direction that Lilly has taken by moving into rheumatology and dermatology. Additionally, he points to the change in…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Romania Jorge Ruiz Benecke of AbbVie Romania outlines how the affiliate attained its leading position in the Romanian pharma market, the importance of agility in the decision-making process, and how he has fostered a culture of diversity, transparency, and inclusivity. He also reveals how AbbVie is actively collaborating with national associations…

Mexico Novartis Mexico Country President Fernando Cruz outlines the new normal for Mexican healthcare post-regulatory reform, how the company’s global reshuffle has impacted Mexican operations, and the challenges inherent in bringing innovative treatments to what is a still-developing market.   A new set of rules is emerging in Mexican healthcare Fernando,…

Romania Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a state-of-art stem cell therapy. She highlights the organisational changes in the last year, and how they have been inducive to double-digit growth for Takeda. Additionally, she reveals…